<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045482</url>
  </required_header>
  <id_info>
    <org_study_id>SARO.19.003 Part B</org_study_id>
    <nct_id>NCT05045482</nct_id>
  </id_info>
  <brief_title>Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease</brief_title>
  <official_title>A Phase 1, Open-Label Extension Groups Study in Subjects Having Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zydus Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zydus Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with&#xD;
      Cirrhosis due to Cholestatic Liver Disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic impairment study in subjects with cirrhosis secondary to cholestatic disease at a&#xD;
      single and multiple once daily doses of Saroglitazar Magnesium needs to be conducted per&#xD;
      discussion with FDA. Thus, an extension study has been added.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Saroglitazar Magnesium at 1 mg and 2 mg single and once a daily multiple dose administration.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the plasma PK of Saroglitazar (parent compound)</measure>
    <time_frame>Serial PK blood samples will be collected on Day1 and Day 28 (1 pre-dose sample and serial post dose sampling till 24 hours post dose on both days)</time_frame>
    <description>To measure the plasma concentration of Saroglitazar (parent compound) and estimate the AUCt following single and once a daily multiple oral doses of 1 mg and 2 mg in subjects with mild, moderate and severe hepatic impairment with cirrhosis due to cholestatic liver disease based on Child-Pugh-Turcotte score compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of Saroglitazar</measure>
    <time_frame>Through study completion, an average of 9 weeks</time_frame>
    <description>Percentage of subjects with clinical &amp; laboratory AEs/SAEs and Treatment emergent AEs/SAEs, coded using the MedDRA following single and once a daily multiple oral doses of 1 mg and 2 mg of Saroglitazar Magnesium in subjects with mild, moderate and severe hepatic impairment with cirrhosis due to cholestatic liver disease based on Child-Pugh-Turcotte score compared to subjects with normal hepatic function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate plasma PK of Saroglitazar metabolite (Saroglitazar sulfoxide)</measure>
    <time_frame>Serial PK blood samples will be collected on Day 1 and Day 28 (1 pre-dose sample and serial post dose sampling till 24 hours post dose on both days)</time_frame>
    <description>To measure the plasma concentration of Saroglitazar metabolite (Saroglitazar sulfoxide) and estimate the AUCt following single and once a daily multiple oral doses of 1 mg and 2 mg in subjects with mild, moderate and severe hepatic impairment with cirrhosis due to cholestatic liver disease based on Child-Pugh-Turcotte score compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the impact of hepatic impairment with cirrhosis due to cholestatic liver disease on the unbound concentration of Saroglitazar in systemic circulation in</measure>
    <time_frame>The blood samples will be collected on Day 1 and Day 28 at pre-dose, 2.0 h and 24.0 h post dose.</time_frame>
    <description>To measure the differences (between day-01 and Day-28) on unbound concentration of Saroglitazar in systemic circulation following single and once a daily multiple oral doses of 1 mg and 2 mg in subjects with mild, moderate and severe hepatic impairment with cirrhosis due to cholestatic liver disease based on Child-Pugh-Turcotte score compared to subjects with normal hepatic function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the trough plasma concentration of Saroglitazar (parent compound)</measure>
    <time_frame>Trough plasma sample will be collected at pre-dose on Visit 3 (on day 8), Visit-4 (On day 15) and at Visit 5 (on day 22). Additional PK sample will be collected at 168.0 hours post dose of day 28 (i.e. on Day 35 Â±3D)</time_frame>
    <description>To evaluate the trough plasma concentration of Saroglitazar following single and once a daily multiple oral doses of 1 mg and 2 mg in subjects with mild, moderate and severe hepatic impairment with cirrhosis due to cholestatic liver disease based on Child-Pugh-Turcotte score compared to subjects with normal hepatic function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the plasma PK of Saroglitazar (parent compound)</measure>
    <time_frame>Serial PK blood samples will be collected on Day1 and Day 28 (1 pre-dose sample and serial post dose sampling till 24 hours post dose on both days)</time_frame>
    <description>The plasma concentration of Saroglitazar (parent compound) will be measured to estimate the Cmax following single and once a daily multiple oral doses of 1 mg and 2 mg in subjects with mild, moderate and severe hepatic impairment with cirrhosis due to cholestatic liver disease based on Child-Pugh-Turcotte score compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the plasma PK of Saroglitazar metabolite (Saroglitazar sulfoxide)</measure>
    <time_frame>Serial PK blood samples will be collected on Day 1 and Day 28 (1 pre-dose sample and serial post dose sampling till 24 hours post dose on both days)</time_frame>
    <description>The plasma concentration of Saroglitazar metabolite (Saroglitazar sulfoxide) will be measured to estimate the Cmax following single and once a daily multiple oral doses of 1 mg and 2 mg in subjects with mild, moderate and severe hepatic impairment with cirrhosis due to cholestatic liver disease based on Child-Pugh-Turcotte score compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Cirrhosis</condition>
  <condition>Cholestatic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Saroglitazar Magnesium 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study drug will be administered from Day 1 to Day 28 once daily in the morning before breakfast without food.&#xD;
Study drug -Saroglitazar Magnesium tablets; Dosage form- Tablets (immediate release); Dose- 1 mg/day; Frequency- One tablet per day (in the morning before breakfast without food); Duration of treatment- 28 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saroglitazar Magnesium 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study drug will be administered from Day 1 to Day 28 once daily in the morning before breakfast without food.&#xD;
Study drug -Saroglitazar Magnesium tablets: Dosage form- Tablets (immediate release); Dose- 2 mg/day; Frequency- One tablet per day (in the morning before breakfast without food); Duration- 28 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 1 mg</intervention_name>
    <description>Group-8: Total of 12 subjects will be enrolled in the Group-8. Group 8A (n=3, consist of mild hepatic impairment subjects); Group 8B (n=3, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).</description>
    <arm_group_label>Saroglitazar Magnesium 1 mg</arm_group_label>
    <other_name>Subjects will be domicile in clinic from Day -1 till Day 5 or Day 7 and from Day 27 through day 29 for PK sampling procedures.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 2 mg</intervention_name>
    <description>Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).</description>
    <arm_group_label>Saroglitazar Magnesium 2 mg</arm_group_label>
    <other_name>Subjects will be domicile in clinic from Day -1 till Day 5 or Day 7 and from Day 27 through day 29 for PK sampling procedures.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
          1. Ability to comprehend and willingness to sign a written ICF for the study.&#xD;
&#xD;
          2. Male or female aged 18 to 80 years (inclusive) at the time of signing the ICF.&#xD;
&#xD;
          3. Body mass index within the range 18.0 to 48.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          4. Females must be non-pregnant, non-lactating and of non-childbearing potential or using&#xD;
             highly efficient contraception for the full duration of the study.&#xD;
&#xD;
          5. Females of child-bearing potential and males must agree to use contraception for the&#xD;
             full duration of the study.&#xD;
&#xD;
          6. Ability to swallow and retain oral medication.&#xD;
&#xD;
             For Subjects in Groups 8 and 9 (Hepatic impairment group but with cirrhosis from&#xD;
             cholestatic liver disease):&#xD;
&#xD;
          7. Participants having documented history of hepatic impairment with cirrhosis due to&#xD;
             cholestatic liver disease in Groups 8 and 9 will be classified in sub groups at&#xD;
             screening based on CPT score. If the hepatic impairment classification for the subject&#xD;
             is not the same at screening and Day -1, enrolment of the subject into a hepatic&#xD;
             category group will be at the discretion of the hepatology Investigator.&#xD;
&#xD;
          8. Laboratory test values for hepatic impairment subjects Groups 8 (8A, 8B, 8C) and 9&#xD;
             (9A, 9B, 9C) must be clinically acceptable to the Investigator and meet all the&#xD;
             following parameters at Screening:&#xD;
&#xD;
               1. ALT/AST value â¤ 10 Ã upper limit of normal (ULN)&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) â¥ 750/mm3&#xD;
&#xD;
               3. Platelets â¥ 25,000/mm3&#xD;
&#xD;
               4. Hemoglobin â¥ 8 g/dL&#xD;
&#xD;
               5. Î±-fetoprotein &lt; 50 ng/mL or 50-80 ng/mL with negative imaging study (US, CT,&#xD;
                  MRI).&#xD;
&#xD;
             For Subjects in Groups 8D and 9D (normal hepatic function groups):&#xD;
&#xD;
          9. Subjects should be in good health as determined by no clinically significant findings&#xD;
             in the medical history, physical examination, vital signs, 12-lead electrocardiograms&#xD;
             (ECGs), or laboratory examinations at Screening or Check-in.&#xD;
&#xD;
         10. Laboratory test values within normal limits or considered not clinically significant&#xD;
             by the Investigator for subjects with normal hepatic function including ALT/AST &lt; 1.2&#xD;
             Ã ULN at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
          1. Any significant, unstable medical condition or other instability that would prevent&#xD;
             the subject from participating in the study as determined by the Investigator or&#xD;
             designee.&#xD;
&#xD;
          2. History of malignancy of any type in the last 3 years of screening, with the exception&#xD;
             of the following: in situ cervical or breast cancer or surgically excised non-melanoma&#xD;
             skin cancers (i.e. basal cell or squamous cell carcinoma).&#xD;
&#xD;
          3. History of stomach or intestinal surgery or resection within the six months prior to&#xD;
             screening that would potentially alter absorption and/or excretion of orally&#xD;
             administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair&#xD;
             will be allowed).&#xD;
&#xD;
          4. History of any significant drug allergy (such as anaphylaxis) deemed clinically&#xD;
             relevant by the Investigator.&#xD;
&#xD;
          5. Any major surgery within 3 months of screening.&#xD;
&#xD;
          6. Donation of blood or blood products within 3 months prior to screening.&#xD;
&#xD;
          7. Current active infectious disease requiring systemic antibiotic, antifungal, or&#xD;
             antiviral treatment or symptoms of active infectious disease within the two weeks&#xD;
             prior to screening.&#xD;
&#xD;
          8. Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's Wort, within 21 days prior&#xD;
             to screening, unless deemed acceptable by the Investigator.&#xD;
&#xD;
          9. Receiving or has received any investigational drug within the 30 days or 5 half-lives&#xD;
             (whichever is longer), before receiving Saroglitazar Magnesium.&#xD;
&#xD;
         10. Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73m2 by modification of diet&#xD;
             in renal disease (MDRD) formula at screening.&#xD;
&#xD;
         11. Positive alcohol breath test at the time of check-in or those subjects who have&#xD;
             current alcohol or substance abuse judged by the Investigator to potentially interfere&#xD;
             with subject compliance or subject safety.&#xD;
&#xD;
         12. Positive test for drugs of abuse at screening or admission. Subjects with a positive&#xD;
             test based on a prescribed medication may be enrolled.&#xD;
&#xD;
         13. Any subject with poor peripheral venous access&#xD;
&#xD;
         14. Receipt of blood products within 1 month prior to check in.&#xD;
&#xD;
         15. Human immunodeficiency virus (HIV) type 1 antibody positive at screening for all&#xD;
             groups.&#xD;
&#xD;
             For Subjects in Groups 8 and 9 (Hepatic impairment group but with cirrhosis from&#xD;
             cholestatic liver disease):&#xD;
&#xD;
         16. Other known cause of liver disease such as NASH, alcoholic steatohepatitis (ASH),&#xD;
             autoimmune hepatitis, or acute or chronic viral hepatitis as determined by the&#xD;
             Investigator and subject's medical records.&#xD;
&#xD;
         17. Subjects who have had a change in hepatic disease status within 30 days of screening,&#xD;
             as documented by the participant's medical history and deemed clinically significant&#xD;
             by the Investigator.&#xD;
&#xD;
         18. Subjects having -&#xD;
&#xD;
               1. History of gastrointestinal bleeding within 1 month prior to screening.&#xD;
&#xD;
               2. Current functioning organ transplant.&#xD;
&#xD;
               3. Evidence of severe ascites requiring frequent paracentesis in the opinion of&#xD;
                  investigator.&#xD;
&#xD;
         19. Subjects who use or intend to use any over the counter (vitamins, minerals, and&#xD;
             phytotherapeutic/herbal/plant-derived preparations) or prescription medications within&#xD;
             30 days or 5 half-lives (whichever is longer) prior to enrolment, with the exception&#xD;
             of hormone replacement therapy and therapies for hepatic disease and treatments of&#xD;
             associated disorders that have been stable for at least 30 days prior to screening and&#xD;
             until Day 1, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
             For Control with Normal Hepatic Function:&#xD;
&#xD;
         20. Subjects who have taken any prescription medications or over-the-counter medications,&#xD;
             including herbal products, within 14 days prior to start of study drug dosing, with&#xD;
             the exception of vitamins, acetaminophen, hormonal contraceptive medications and/or&#xD;
             any other over-the-counter product approved by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deven V Parmar, MD, FCP</last_name>
    <role>Study Director</role>
    <affiliation>Zydus Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farheen Shaikh</last_name>
    <phone>+971556207901</phone>
    <email>farheen.arifahmed@zydusdiscovery.ae</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Bainbridge, JD</last_name>
    <phone>1-609-559-0760</phone>
    <email>jbainbridge@zydustherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj Vuppalanchi, MD</last_name>
      <phone>317-278-1664</phone>
      <email>rvuppala@iu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Saroglitazar Magnesium</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Cholestatic Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

